Clinical Trials Logo

Histiocytosis, Langerhans-Cell clinical trials

View clinical trials related to Histiocytosis, Langerhans-Cell.

Filter by:

NCT ID: NCT00890747 Completed - Clinical trials for Unspecified Adult Solid Tumor, Protocol Specific

Sunitinib Malate in Treating HIV-Positive Patients With Cancer Receiving Antiretroviral Therapy

Start date: August 2009
Phase: Phase 1
Study type: Interventional

This phase I trial studies the side effects and the best dose of sunitinib malate in treating human immunodeficiency virus (HIV)-positive patients with cancer receiving antiretroviral therapy. Sunitinib malate may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.

NCT ID: NCT00588536 Completed - Clinical trials for Langerhans Cell Histiocytosis

Study of Sequential Administration of Oral 6-Thioguanine After Methotrexate in Patients With LCH

Start date: January 1995
Phase: Phase 2
Study type: Interventional

The objective of this study is to determine the incidence of complete and partial response and the duration of response in patients with Langerhans Cell Histiocytosis (LCH) treated with sequential administration of oral 6-Thioguanine (6-TG) after Methotrexate (MTX).

NCT ID: NCT00276757 Completed - Clinical trials for Childhood Langerhans Cell Histiocytosis

Combination Chemotherapy in Treating Young Patients With Langerhans Cell Histiocytosis

Start date: April 2001
Phase: N/A
Study type: Interventional

RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of Langerhans cell histiocytosis, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may be an effective treatment for Langerhans cell histiocytosis. PURPOSE: This randomized clinical trial is studying combination chemotherapy to see how well it works in treating young patients with Langerhans cell histiocytosis.

NCT ID: NCT00176865 Completed - Clinical trials for Hemophagocytic Lymphohistiocytosis

Stem Cell Transplant for Immunologic or Histiocytic Disorders

Start date: August 2002
Phase: Phase 2
Study type: Interventional

This study tests the clinical outcomes of a preparative regimen of fludarabine (FLU), anti-thymocyte globulin (ATG)/or Campath, and melphalan; followed by hematopoietic stem cell transplant, and a post transplant regimen of Cyclosporin A (CsA) in patients with immunologic or histiocytic disorders. The researchers hypothesize that this regimen will have a positive effect on post transplant engraftment and the incidence of graft-versus-host-disease (GVHD). Patients will be randomized biologically into one of 3 arms based upon donor availability: (a) human leukocyte antigen (HLA) genotypic matched sibling donor, (b) HLA phenotypic matched unrelated peripheral blood stem cell (PBSC) donor, (c) two HLA 0-2 antigen mismatched unrelated cord blood donors (double cord).

NCT ID: NCT00048373 Completed - Clinical trials for Histiocytosis, Langerhans-Cell

Treatment of Resistant Langerhans Cell Histiocytosis With ENBREL

Start date: October 2001
Phase: Phase 2
Study type: Interventional

The purpose of this study is to learn about the response of Langerhans cell histiocytosis (LCH) to Enbrel in patients who have failed to respond to standard therapies. We are also looking specifically at what side effects Enbrel has on patients. We expect to enroll 20 patients on this study and anticipate the subjects active participation to last up to one year.